Humedics Announces Appointment of Karsten Damgaard-Iversen as CEO

Reinforcement of senior management team to leverage growth phase of Humedics

Berlin. The Board of Humedics GmbH is pleased to announce a reinforcement of the senior team of the company with Karsten Damgaard-Iversen (MBA, BScEE), who will take up the role of CEO as of June 1, 2017. Erwin de Buijzer will stay on as managing director (MD) with the title Chief Operations Officer (COO). Read more

The Berlin Institute of Health adopts the digital laboratory data management platform from the Berlin-based start-up labfolder

The Berlin-based start-up labfolder has won a second major client: beginning in April 2017, the Berlin Institute of Health (BIH) will be introducing labfolder’s electronic lab notebook as part of its quality initiative. The innovative data management software will be made available to more than 4,000 researchers at the Charité and the Max Delbrück Center for Molecular Medicine. Read more

CEVEC, medac and Provecs Medical enter into far-reaching adenoviral vector collaboration in oncology

  • Project will cover the entire process from R&D up to manufacturing and clinical development of adenoviral vectors for medac’s oncology products using CEVEC’s proprietary CAP(R)GT Technology

  • Collaboration is next step in setting CAP(R)GT as global standard in adenoviral gene therapy

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, Provecs Medical GmbH (Provecs), a biopharmaceutical company specialized in the development of cancer microenvironment immunotherapeutics based on adenoviral vector technology , and medac Gesellschaft fuer klinische Spezialpraeparate GmbH (medac), a pharmaceutical company specialized in the diagnosis and treatment of oncological, urological and autoimmune diseases, today announced that the companies have agreed on a broad collaboration for the research, development, manufacture and clinical development of adenoviral vectors for use in oncology indications. Read more

CEVEC licenses CAP(R) technologies for the development and commercialization of vaccines against Zika Virus infections

Agreement marks an important step in establishing CAP(R) technologies as the new global industrial standard for viral vector and vaccine development

Cologne. CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that it has signed an exclusive license agreement with NewLink Genetics (NASDAQ:NLNK) for use of its proprietary CAP(R)GT and CAP(R)Go cell lines in the development and commercialization of products for the treatment and prophylaxis of Zika virus infections. Read more

LiMAx test enables better timing of liver surgery for colorectal liver metastatic patients after chemotherapy

Determination of liver function is crucial to assess patient’s eligibility for safe liver resection

Berlin.  Humedics GmbH, a specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient, today announced that two studies show the potential of the LiMAx test to better assess the eligibility of colorectal cancer patients for liver metastases resection after chemotherapy. The LiMAx test was used to explore the effects of oxaliplatin-based chemotherapy on liver function. Read more

CEVEC submits Biologics Master File (BB-MF) for CAP(R) Technology to the U.S. FDA

  • Submission represents an important step towards establishing CAP(R)GT and CAP(R)Go technologies as the new industrial standards for viral vaccines, commercial-scale gene therapy vectors and recombinant protein production
  • CEVEC’s CAP(R) technology licensees can reference BB-MF, simplifying and accelerating their regulatory approval process for a CAP(R)-derived product.

Read more

Peppermint VenturePartners closes Series-C financing round of Miracor Medical Systems GmbH

Miracor’s Chairman of the Board: “We are proud to have PVP joining our Investors”

Berlin. Peppermint VenturePartners led the recent Series-C financing of Miracor Medical Systems GmbH with an investment from its Peppermint CBF-1 fund. The total amount raised in the Series-C is currently € 7 Million. Miracor seeks to complete Series-C with another € 8 Million. Read more

Labfolder signs Agreement with Max Planck Society for organization-wide use of laboratory data digital platform

  • Contract provides up to 11,000 Max Planck scientists access to use labfolder for digital laboratory data Management
  • First organization-wide digital laboratory data management deal for a Research institute across all disciplines globally
  • Long-term collaboration between labfolder and the Max Planck Society to further develop the platform
  • Digitalization of laboratory data management is a key driver in future scientific Innovation

Read more

CEVEC and Paragon Bioservices enter into comprehensive collaboration to roll out CAP(R) technologies in North America

  • Agreement establishes Paragon as CEVEC’s preferred partner for contract development and manufacturing (CDMO) services in North America
  • Companies will conduct coordinated marketing and business development activities to establish CEVEC’s CAP(R) technologies as a new standard for gene therapy vector production
  • Collaboration includes developing a scalable clinical production process for AAV-based gene therapy vectors based on the CAP(R)GT platform

Read more

Humedics submists Marketing authorizaion application for the diagnostic agent with the LiMAx test

Humedics GmbH, a specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient, today announced that the company has submitted the marketing authorization application for the diagnostic agent necessary for the performance of the LiMAx test. The dossier was submitted in Germany, UK and Austria. Read more

CEVEC’s CAP®GT sets a new standard through RCA-free production of adenoviral vectors for gene therapy applications

  • CAP®GT technology for fully scalable industrial adenoviral vector production with proven absence of replication-competent adenovirus (RCA)
  • CAP®GT technology is underway to replace HEK293 as current production host for adenoviral vector

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that the Company’s proprietary cell-expression system, CAP®GT, has delivered the production of safe adenoviral (AV) gene therapy vectors with the proven absence of RCAs. Read more

CEVEC intensifies its marketing activities, presenting at various renowned scientific conferences in Europe and the US

Cologne, Germany

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that the Company will present at the following renowned international scientific cell culture and gene therapy conferences in Europe and the US to promote the unique and superior features of its proprietary platform technologies CAP®Go and CAP®GT to industrial players in biopharmaceutical and gene therapy applications. Read more

CEVEC and Beckman Research Institute of City of Hope enter into a cooperation and license agreement on CEVEC’s proprietary CAP(R)GT technology

  • CEVEC’s CAP(R)GT technology enables fully scalable lentiviral and RCA (replication competent adenovirus)-free adenoviral vector production
  • Further step to establish CEVEC’s CAP(R)GT technology as the industrial standard for the production of lentiviral and adenoviral gene therapy vectors

Read more

Use of LiMAx test leads to reduction in post-hepatectomy liver failure and related mortality

Humedics GmbH, a specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient, today announced results of a retrospective study investigating the impact of the LiMAx test on clinical patient outcome after hepatectomy. Study results showed that the use of the LiMAx test led to reductions in post-operative liver failure and to a decrease of liver failure related mortality. Read more

Helmholtz validation funding extended, facilitating further projects

Developing pioneering technologies and making them attractive for industry often requires a great deal of patience and perseverance. The Helmholtz Validation Fund (HVF) is therefore providing support to a number of particularly promising projects carried out by research teams in the Helmholtz

Association. A total of 21 projects were selected for the first funding period from 2011 to 2015. Following a successful evaluation process, the programme will now continue from 2016 to 2020. The first three projects to be funded in the new programme phase were selected this December by the experts on the decisionmaking board. These projects could pave the way to discovering new and better ways of diagnosing and treating diseases such as cancer, osteoporosis and Alzheimer’s. Read more

Emperra Digital Diabetes Care closes Series B round with Robert Bosch Venture Capital GmbH joining as a new investor

Emperra, a German start-up that has created a digital diabetes management solution consisting of smart hardware and software, has completed a Series B financing round of USD 3.1 million, with Robert Bosch Venture Capital GmbH (RBVC), a corporate venture capital company of the Bosch Group, joining the existing investors Peppermint VenturePartners and Investitionsbank des Landes Brandenburg. CEO Dr. Krey and CTO Dr. Schildt, management of Emperra, also participated in the round. The funds will be used for further product development and to accelerate international growth, predominantly in the United States and Europe. Read more

CEVEC and BioLamina combine technology leadership for commercial production of recombinant laminins for ex vivo cell therapies

  • CEVEC adds laminins as CAP®Go application in the field of ex vivo cell culture products for cell therapies
  • CEVEC’s CAP®Go to displace HEK293 and CHO cell lines in GMP manufacturing
  • BioLamina to further grow its leading high quality ex vivo cell culture laminin product portfolio
  • First commercial CAP®Go-derived laminin, LN-521, expected to be globally available in 2016

Read more

CEVEC and CellGenix sign collaboration and license agreement for CEVEC’s proprietary CAP®Go technology

Cologne and Freiburg

  • CEVEC provides expertise and grants license for the production of selected growth and differentiation factors based on CAP®Go technology
  • CEVEC further expands CAP®Go applications into the field of GMP-grade ex vivo cell culture products for cell therapies
  • CellGenix provides expertise to develop and manufacture CAP®Go-derived high-quality proteins for clinical cell culture needs
  • CellGenix complements its protein production platform with human expression technology

Read more